6 completed, 2 terminated, 1 active not recruiting, 1 approved for marketing. 6 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Terminated 1 |
Follow C3 Glomerulonephritis: new trials by email Literature Review of C3 Glomerulonephritis trials Research Report on C3 Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Aliskiren, Enalapril - C3 Glomerulopathy, Membranoproliferative Glomerulonephritis | Phase 2 | Recruiting | Region Skane | 30 | 2020-10-01 | 2025-06-22 |
| Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study Non contrast-enhanced magnetic resonance imaging - C3 Glomerulonephritis, C3 Glomerulopathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 7 | 2018-12-06 | 2021-11-26 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2018-06-12 | 2022-10-14 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies APL-2 - IgA Nephropathy, Lupus Nephritis | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 21 | 2018-02-26 | 2025-02-13 |
| A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Danicopan - C3 Glomerulonephritis, Dense Deposit Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 6 | 2017-08-09 | 2021-11-04 |
| Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease CDX-1135 - Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II | Phase 1 | Terminated | Celldex Therapeutics | 1 | 2013-01-01 | 2014-03-07 |
| C3G/Primary IC-MPGN EAP Pegcetacoplan - C3G, IC-MPGN | Approved for marketing | Apellis Pharmaceuticals, Inc. | 2025-11-06 |
Glomerulonephritis, Membranoproliferative (11) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Lupus Nephritis (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Glomerulonephritis (11) · Immune System Diseases (11) · Kidney Diseases (11) · Male Urogenital Diseases (11) · Nephritis (11) · Urogenital Diseases (11) · Urologic Diseases (11) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Lupus Erythematosus, Systemic (1) · Skin and Connective Tissue Diseases (1)
pegcetacoplan (4) · danicopan (3) · Enalapril (1) · aliskiren (1) · rhoA GTP-Binding Protein (1)
Apellis Pharmaceuticals, Inc. (5) · Alexion Pharmaceuticals, Inc. (3) · Celldex Therapeutics (1) · Mario Negri Institute for Pharmacological Research (1) · Region Skane (1)
United States (7) · Australia (5) · Italy (5) · Netherlands (5) · Belgium (4) · United Kingdom (4) · Argentina (3) · Brazil (3) · France (3) · Spain (3) · Switzerland (3) · Austria (2) · Czechia (2) · Israel (2) · Japan (2)
Carla Nester, MD, MSA (1) · Diana Karpman (1) · Richard Smith, MD (1)
PMID 36423588, PMID 42133432, PMID 37036696, PMID 37926085, PMID 41337715
2017 (2), 2016 (1), 2019 (1), 2023 (1)